Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 1.00 |
| ▸ | KIT | P10721 | 11/20 | 1.00 |
| ▸ | FLT3 | P36888 | 10/20 | 1.00 |
| ▸ | AXL | P30530 | 6/20 | 1.00 |
| ▸ | HIPK4 | Q8NE63 | 6/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 1.00 |
| ▸ | FLT1 | P17948 | 6/20 | 1.00 |
| ▸ | CSF1R | P07333 | 5/20 | 1.00 |
| ▸ | RET | P07949 | 5/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 5/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 1.00 |
| ▸ | PLK4 | O00444 | 5/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 5/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 5/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 1.00 |
| ▸ | STK3 | Q13188 | 5/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 5/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 5/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 5/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471506 | 0.91 | KDR (0.83) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL4474170 | 0.90 | KDR (0.82) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL4474877 | 0.89 | KDR (0.80) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL4486611 | 0.88 | KDR (1.00) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL6092809 | 0.88 | KDR (1.00) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL4467133 | 0.88 | KDR (1.00) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL4477648 | 0.88 | KDR (1.00) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL4478814 | 0.88 | KDR (0.78) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL4477423 | 0.88 | KDR (0.78) | KDRKITFLT3AXLHIPK4 | |
| SCHEMBL4472667 | 0.88 | KIT (1.00) | KDRKITFLT3AXLHIPK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242086-A1 | THERAPEUTIC BIOMATERIAL THAT ATTENUATES THE FOREIGN BODY RESPONSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-07-31 | — | — | US | claimed |
| CN-118520620-A | Mu PMU arrangement method considering observation redundancy distribution and distribution network topology change | 广东电网有限责任公司电力调度控制中心 | 2024-08-20 | — | — | CN | claimed |
| WO-2023219948-A1 | THERAPEUTIC BIOMATERIAL THAT ATTENUATES THE FOREIGN BODY RESPONSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-11-16 | — | — | WO | claimed |
| EP-2588098-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | Alcon Research, Ltd. (US) | 2013-05-08 | — | — | EP | claimed |
| US-20120004245-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALCON RESEARCH, LTD. (US) | 2012-01-05 | — | — | US | claimed |
| WO-2012003141-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALCON RESEARCH, LTD. (US) | 2012-01-05 | — | — | WO | claimed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | claimed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | claimed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | claimed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | claimed |
| US-20250242086-A1 | THERAPEUTIC BIOMATERIAL THAT ATTENUATES THE FOREIGN BODY RESPONSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4584556-A1 | METHOD AND SYSTEM FOR DETERMINING INITIAL HEADING ANGLE | Septentrio N.V. (BE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025096145-A1 | PROBATION OF DIRECT MEMORY ACCESS DEVICE USED FOR DIRECT DEVICE ASSIGNMENT | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096146-A1 | DETECTION OF MALICIOUS DIRECT MEMORY ACCESS DEVICE USED FOR DIRECT DEVICE ASSIGNMENT | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240372365-A1 | METHOD AND SYSTEM FOR AN ELECTRICITY DISTRIBUTION LINE | BAUER ALBERTO (AE) | 2024-11-07 | — | — | US | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885KIT 394/4885FLT3 29/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | KDR 391/4885KIT 361/4885FLT3 16/4885 |
| US-20120004245-A1 | COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES | ALDH1A2, UACA, VHL | KDR 210/4885KIT 2839/4885FLT3 3809/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885KIT 394/4885FLT3 29/4885 |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 462/4885KIT 359/4885FLT3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.